Acute Ischemic Stroke Therapeutics Market: Growth Opportunities led by Athersys Inc. and Bayer AG

New York, November 28, 2022 /PR Newswire/ — Acute Ischemic Stroke (AIS) Treatment Market size is US$1,524.49 million Between 2022 and 2027, CAGR 5.72%Market growth is driven by the rising prevalence of high-risk factors. Additionally, the use of technologies such as TBI is expected to boost the market growth.

This report is Acute Ischemic Stroke (AIS) Therapeutics Market Segmentation by Type (Thrombolytics, Anticoagulants, Antiplatelets, Antihypertensives), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), When Geography (North America, Europe, Asiaand the rest of the world (ROW). Request a Free Sample Report

Acute Ischemic Stroke Treatment Market – Vendors

The global AIS therapeutics market is a fragmented market with a variety of large and small players. Large companies are focusing on increasing strategic alliances and acquisitions to consolidate the market in order to increase their market share. Additionally, these vendors continuously innovate their products. Some of the major vendors are listed below.

• Athersys, Inc.

• Bayer AG

• Biogen K.K.

• Boehringer Ingelheim International GmbH

• Medtronic Plc

• Nono Co., Ltd.

• SanBio Co., Ltd.

• striker company

• Amgen

• AstraZeneca

• Bristol-Myers Squibb Company

• Daiichi Sankyo Co., Ltd.

• F. Hoffmann La Roche

• Johnson & Johnson

• Merck

• Sanofi SA

• Teva Pharmaceutical Co., Ltd.

Product Insights and News

• athersys.com: The company offers acute ischemic stroke treatments such as Repatha.

• Bayer.com – The Company offers acute ischemic stroke treatments such as Brilinta ticagrelor tablets.

• biogen.com – The Company offers acute ischemic stroke treatments such as Masters 2 MultiStem cell therapy.

For more insight into the products and growth strategies adopted by vendors, visit buy report

Acute Ischemic Stroke Therapeutics Market – Geographic Landscape

North America estimated to account for 38% of market growth during the forecast period. Market growth in this region is due to factors such as expected approval of late-stage pipeline molecules such as BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem and NA-1. Moreover, various diagnostics and drugs for the treatment of stroke are expected to become available in this region, which will boost the market growth.

story continues

Acute Ischemic Stroke Treatment Market – Market segmentation

The thrombolytics segment is estimated to contribute the highest share of global market growth during the forecast period. One of the factors behind the growth of this segment is the availability of US FDA-approved treatments for AIS. For example, the IV alteplase drug is marketed under the brand name Activase. It is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). Download a free sample report

What are the key data covered in this Acute Ischemic Stroke (AIS) Treatment Market report?

• CAGR of the market during the forecast period

• Detailed information on the factors driving the growth of the Acute Ischemic Stroke (AIS) Therapeutics market during 2023-2027

• Accurate Estimation of Acute Ischemic Stroke (AIS) Therapeutics Market Size and Contribution to the Parent Market

• Accurate prediction of upcoming trends and changes in consumer behavior

• Acute Ischemic Stroke (AIS) Therapeutic Market Growth Across APAC North America, Europe, middle east When AfricaWhen South America

• In-depth analysis of market competitive landscape and vendor details

• Comprehensive Analysis of Factors Challenging the Growth of Acute Ischemic Stroke (AIS) Therapeutics Market Vendors

Technavio’s library contains over 17,000 reports covering over 2,000 new technologies. Apply Now for Basic Plan US$5,000 Get lifetime access to Technavio Insights

Related reports:

APAC Acute Myeloid Leukemia (AML) Treatment Market By Type and Region – Forecasts and Analysis from 2022 to 2026: The market size for acute myeloid leukemia (AML) treatment in APAC is US$277.03 million From 2021 to 2026, the market growth momentum will accelerate at a CAGR of 12.83%.

Alzheimer’s disease drug market By drug class and region – forecast and analysis from 2022 to 2026: The size of the market for Alzheimer’s disease drugs is US$3.99 billion From 2021 to 2026, the market growth momentum will accelerate at a CAGR of 8.76%.

Browse Technavio “Health careresearch report

table of contents

1.executive summary

2 Market Outlook

3 Market size

4 Five Forces Analysis

Market Segmentation by 5 Types

6 Market Segmentation by Distribution Channel

7 Customer Situation

8 Geographical landscape

9 Drivers, challenges and trends

10 Vendor Landscape

11 vendor analysis

12 Appendix

About Technavio

Technavio is the world’s leading technology research and advisory firm. Their research and analysis focuses on emerging market trends, with actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market position. provide.

With over 500 expert analysts, Technavio’s report library consists of over 17,000 reports covering 800 technologies across 50 countries. Their customer base consists of companies of all sizes, including over 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify existing and potential market opportunities and compete within changing market scenarios. Evaluate power.

contact address

Technavio Research
Jessie Maida
Media & Marketing Executive
USA: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

View original content and download multimedia:https://www.prnewswire.com/news-releases/acute-ischemic-stroke-therapeutics-market-growth-opportunities-led-by-athersys-inc-and-bayer-ag—technavio-301687079.html

source technavio